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Summary 
The Janus family of kinases (JAKs)  has been shown to be involved in the signal transduction 
of a number of cytokine receptors. Recently, we have cloned a novel JAK family member, JAK3, 
that is expressed in natural killer and activated T cells and is coupled functionally and physically 
to the interleukin 2 (IL-2) receptor in these cells. Here we report that JAK3 was expressed at 
low but detectable levels in human monocytes. In contrast, JAK3 expression was strongly induced 
during activation by interferon 3' (IFN-3') or lipopolysaccharide. Moreover, JAK3 became tyrosine 
phosphorylated in response to IL-2,  IL-4, and IL-7 but not response to IFN-3' or granulocyte/ 
macrophage colony-stimulating factor. Together, these findings suggest that JAK3 is functionally 
important in activated monocytes and cells of the myeloid lineage and is involved in signaling 
responses  of cytokines that use the common "),-chain of the IL-2 receptor. 
M 
any of the regulatory networks that govern the matu- 
. ration and function of leukocytes are  mediated by 
cytokines that bind to receptors of the hematopoietin family 
(1). Although the proteins of this structurally related family 
do not possess intrinsic tyrosine kinase activity, tyrosyl phos- 
phorylation is  an early  and requisite event in  the  signal 
transduction pathways of many of these receptors suggesting 
the involvement of cytoplasmic protein tyrosine kinases (2). 
Recently, the nonreceptor tyrosine kinases belonging to the 
Janus (JAK) 1 family (JAK1, JAK2, and Tyk2) have emerged 
as key elements in the signaling pathway elicited by the in- 
terferons as well as several cytokines that use hematopoietin 
family receptors (3, 4). Binding of these cytokines to their 
respective receptors results in the tyrosine phosphorylation 
of various combinations of  JAK family kinases. For example, 
Tyk2 and JAK1 are coupled to the receptors for IFN-odfl 
(5), whereas IFN-3' induces phosphorylation of JAK1 and 
JAK2 (6). 
1 Abbreviation  used in this paper: JAK, Janus  family of kinases. 
The contents of this publication do not necessarily reflect the views or 
policies  of the Department of Health and Human Services,  nor does mention 
of trade names, commercial products, or organizations imply endorsement 
by the U.S. Government. 
We recently have cloned a new member of the JAK family, 
JAK3 (7). Unlike the other JAKs that are widely expressed, 
JAK3 is expressed predominantly in NK cells and activated 
T cells (7). Moreover, we have shown JAK3 to be function- 
ally coupled to the IL-2 receptor in these cells (8) consistent 
with membership of the IL-2 receptor fl and 1, chains in the 
hematopoietin family. The IL-2 receptor 3' chain is shared 
with the receptors for IL-4 and IL-7 and therefore has been 
referred to as the common 3' chain (%) (9, 10). Consistent 
with this model, JAK3 also has been shown to be function- 
ally linked to the IL-4 receptor in T  cells (8,  11). 
Human monocytes express several hematopoietin receptors 
including those for GM-CSF (12), IL-3 (13), and IL-6 (14), 
as well as receptors for IL-2, IL-4, and IL-7 all of which use 
% (15, 16). IL-2 and IL-7 both activate human monocytes 
by inducing genes such as TNF-c~,  IL-6,  IL-8, and IL-1B 
(15, 17). In contrast, although IL-4 can stimulate some mono- 
cytic functions such as antigen presentation (18, 19), it also 
can be directly inhibitory or antagonize monocyte responses 
to IFN-3', IL-2, or IL-7 (17). Although the biological effects 
of these cytokines on monocytes are well documented, the 
biochemical mechanisms through which these responses are 
mediated remain unclear. 
JAK3 expression  previously was demonstrated in a mu- 
fine myeloid cell line (11, 20), however, the protein was un- 
detectable in resting human peripheral blood monocytes (8, 
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analyzing the regulation of  JAK3 expression in human mono- 
cytes. We found that JAK3 was constitutively present in the 
factor-dependent M07e and TF-1 cell lines. In contrast, JAK3 
was expressed at very low levels in resting monocytes. How- 
ever, it was strongly induced during monocyte activation by 
LPS, IFN-% and other cytokines. We also ascertained whether 
the receptors for IL-2, IL-4, and IL-7 were functionally cou- 
pled to JAK3 in human peripheral  monocytes and myeloid 
cell lines.  In these cells,  we show that JAK3 was tyrosine 
phosphorylated  in response to these cytokines, but not by 
IFN-T or GM-CSF.  These data suggest that JAK3 is cou- 
pled to several cytokine receptors that  share  the %,  and is 
likely to be an important signal transduction molecule in the 
cytokine regulation  of monocyte functions. 
Materials and Methods 
Cell Culture.  Monocytes were purified from PBMC by cen- 
trifugal elutriation  as described elsewhere (21). The purity of the 
monocyte preparation used in this study was 93 +  3% as assessed 
by morphology on Giemsa-stained cytocentrifuge preparations and 
flow cytometry using the monocyte-specific mAb LeuM3. Periph- 
eral blood monocytes, U937, and THP-1 cells were cultured  in 
RPMI 1640 (Advanced Biotechnologies, Inc., Columbia, MD), con- 
taining 100 U/ml Penicillin, 100 #g/ml streptomycin, 2 mmol/liter 
r-glutamine,  20 mmol/liter Hepes (GIBCO BILL, Gaithersburg, 
MD), and 10% heat-inactivated fetal bovine serum (Hyclone Labora- 
tories,  Logan, UT). The TF-1 (22) and MO7e (Genetics Institute, 
Cambridge, MA) cell lines were supplemented with 10 ng/ml GM- 
CSF or GM-CSF plus 100 ng/ml stem cell factor (SCF), respec- 
tively. Human recombinant  IFN-T (lot NN9027AX, sp act 2.02 
x  10  v U/mg) was kindly provided by Dr. H. M. Shepard (Genen- 
tech Labs, San Francisco, CA). Human recombinant IL-4, GM-CSF, 
and SCF were obtained from Pcpro Tech (Rocky Hill, NJ). Recom- 
binant  purified I1.-2 from Escherichia coli (lot LP-381, sp. act.  18 
x  106 IU/mg,  and  LPS content  <0.0006  ng/ml)  was  kindly 
provided by Cetus Corp.  (Emeryville, CA). 
Northern Blot Analysis.  For RNA extraction,  5  x  107 mono- 
cytes were plated in 25 ml medium alone or supplemented with 
the indicated cytokines. Total RNA was isolated and Northern blots 
were performed  as described (21). The eDNA probe used cor- 
responded to the JH1 and JH2 domains of  JAK3 (7). All gels were 
inspected visually before transfer and each filter was subsequently 
rehybridized with a probe specific  for G3PDH (Clontech, Palo Alto, 
CA) to ensure that equal amounts  of RNA were loaded in each 
lane. 
Western Blot Analysis.  For analysis of  JAIO protein levels, cells 
were washed in PBS and lysed in buffer containing 1% Triton X-IO0. 
Insoluble material was removed by centrifugation, the protein con- 
tent was determined using a protein assay kit (Bio-Rad Laborato- 
ties, Richmond, CA), and equal amounts of protein for each sample 
were subjected to SDS-PAGE, then electrophoretically transferred 
to Immobilon  (Millipore Corp.,  Bedford, MA) as described (7). 
The resulting filters were probed with a polyclonal rabbit serum 
raised against a synthetic peptide corresponding  to the COOH- 
terminal region of the JAK3 protein (amino acids 1104-1124) (7). 
Bound rabbit antisera was detected using goat anti-rabbit horse- 
radish Peroxidase-linked antisera (Boehringer Mannheim  Corp., 
Indianapolis,  IN) detected by the enhanced chemiluminescence 
(ECL) method (Amersham,  Arlington  Heights,  IL). 
Analysis of  JAK3 Tyrosine  Phosphorflation.  JAK3 was immuno- 
precipitated from darified cell lysates  by incubation with anti-JAK3 
that had been prebound to protein A-Sepharose beads for 2 h at 
4~  (7, 8). The beads were washed with buffer containing 0.1% 
Triton X-100, eluted with 2 x SDS sample buffer, run on 8% SDS- 
PAGE, and transferred to Immobilon.  Antiphosphotyrosine  im- 
munoblotting was performed as previously described (7, 8). Briefly, 
Immobilon membranes were blocked for 1 h at room temperature 
with 2.5% BSA in Tris-buffered Saline (TBS), then incubated with 
antiphosphotyrosine antibody (4G10; Upstate Biotechnology, Inc., 
Lake Placid, NY). The blots were washed with TBS/0.5% Tween 
20, then incubated with horseradish peroxidase-conjugated  sheep 
anti-mouse antibody (Amersham). Bound antibodies were detected 
by ECL. 
Results 
JAK3 Expression in Myeloid Cell Lines and its Phosphoryla- 
tion by IL-2 and 11,-4 in MO7e.  In addition to activated lym- 
phoid cells, JAK3 has been reported to be expressed in the 
growth factor-dependent, murine myeloid cell line 32D but 
not in resting  human  monocytes (8,  11, 20).  In 32D cells 
transfected with the IL-2 receptor, JAK3 was tyrosine phos- 
phorylated upon treatment of the cells with IL-2 (11). These 
data prompted us to ask whether human factor-dependent 
myeloid cell lines with endogenous receptors for IL-2 or IL-4 
might express appreciable JAK3, and if so, would it be phos- 
phorylated  in  response  to  these cytokines?  Therefore,  we 
assayed JAK3 levels in several myeloid cell lines.  Both the 
megakaryocytic leukemia line, MO7e, and the erythroleukemia 
cell line TF-1 (22, 23) were found to express  high levels of 
JAK3 protein that were not significantly altered by the pres- 
ence of growth factors.  In contrast the myeloid lines  U937 
and THP-1 did not have detectable JAK3 (8, and data not 
shown). 
The M07e call  line  has  been reported  to proliferate  in re- 
sponse  to IL-2  or IL-4  but not IL-7  (23).  Therefore,  we ex- 
amined  whether  JAK3 might  be  tyrosine  phosphorylated  upon 
cytokine  stimulation  of  the  endogenous IL-2  or  IL-4  receptors 
in  these  cells.  As shown in  Fig.  I,  in  M07e the  level  of  tyro- 
sine  phosphorylation  of  JAK3 increased  dramatically  in re- 
sponse  to IL-2  or IL-4 (lanes  2 and 3) but not to GM-CSF 
(lane  4).  Peptide  competition  of  the  JAK3 immunoprecipita- 
tion from  IL-2-stimulated  cells  (lane 5) demonstrated  the 
specificity of the JAK3  antibody.  These  filters  were then 
stripped of antibody and probed with anti-JAK3 antibody 
to  confirm  that  with  the  exception  of lane  5,  equivalent 
amounts of  JAK3 were precipitated after cytokine treatment 
(Fig.  1, bottom). These data suggested that JAK3 is likely an 
important  signaling molecule for the endogenous cytokine 
receptors of these myeloid cells. 
JAK3 Is Expressed at Low Levels in Resting Monocytes but 
Is Induced  during Monocyte Activation.  Human peripheral blood 
monocytes respond to IL-2, IL-4, and IL-7 particularly after 
activation  (16, 17, 24, 25). We previously reported that resting 
monocytes express little JAK3 (8). However, monocytes re- 
spond to IFN-~ or LPS with phenotypical, functional,  and 
biochemical changes  including  the upregulation  of several 
genes and heightened responses to cytokine stimulation, and 
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stimulated (lane I) or treated with 1,000 U/ml Ib2 (lanes 2 and 5), 100 
U/ml IL-4 (lane 3), or 100 ng/ml GM-CSF (lane 4) for 10 rain, lysed, 
and JAK3 was immunoprecipitated.  The resulting filters were immuno- 
blotted with monoclonal antiphosphotyrosine  antibody (top), then with 
anti-JAK3 antibody (bottom). 
JAK3 is upregulated during T cell activation (8, 16, 17, 24, 
25). Therefore, we examined whether JAK3 levels might in- 
crease significantly during monocyte activation.  As shown 
in Fig.  2 A,  Northern analysis demonstrated that resting 
monocytes express only low levels ofJAK3 mRNA (lane I) 
but monocytes stimulated for 18 h with IFN-3' (Fig.  2 A, 
lane 2), LPS (lane 3), or both (lane 4) expressed high levels 
of JAK3 mRNA. In these experiments, JAK3 mRNA ap- 
pears as two separate species  due to interference of comigrating 
28S RNA.  Dose titration experiments showed that JAK3 
mRNA could be induced with as little as 4 U/ml IFN-% 
with maximal expression at 100-500 U/ml (Fig. 2 B). JAK3 
mRNA increased rapidly in response to IFN-%  detectable 
within 6 h, maximal by 24 h, and declining thereafter (Fig. 
2 C). When other cytokines were screened for the ability 
to upregulate JAK3 mRNA, we found that both IL-1 and 
TNF-ot induced JAK3 mRNA, but IL-3 and GM-CSF did 
not (data  not shown). 
Because some cytokines are capable of upregulating their 
own receptors,  we next asked whether cytokines likely to 
be linked to JAK3 might also be able to induce  JAK3 expres- 
sion. To this end, monocytes were stimulated for 48 h with 
IFN-3', and/or LPS, or each of three cytokines IL-2, IL-4, 
and IL-7. The data shown in Fig. 3 demonstrate that, in ad- 
dition to induction by IFN-3, and/or LPS, JAK3 mRNA was 
induced by culture with IL-2, but not IL-4 or IL-7. To verify 
that these cytokine treatments result in a concomitant in- 
crease in cellular JAK3 protein, lysate of similarly treated cells 
was immunoblotted  with anti-JAK3 polyclonal antisera. Fig. 
4 A  shows that, as suggested by the mRNA analysis, the 
expression of aJAK3 was induced in response to IL-2, IFN-% 
and LPS, with the latter being by far the most potent stimulus. 
Immunoblotting of lysates from control or LPS-stimulated 
cells in the presence of cognate JAK3 peptide demonstrated 
the specificity of the immunoblotting in monocytes (Fig. 4 
B).  In similar experiments, JAK3 protein was found to be 
expressed in resting monocytes at very low levels, and detect- 
Figure 2.  Induction ofJAK3 mRNA in human monocytes. (A) Monocytes were cultured for 18 h in the presence of medium alone (lane I), 500 
U/ml IFN-3, (lane 2), 50 ng/ml LPS (lane 3), or both IFN-3  ~  and LPS (lane 4). (B) Monocytes were cultured with various doses of IFN-3' for 18 h. 
(C) Monocytes were cultured for various periods of time with 500 U/ml IFN-% Total RNA was extracted, electrophoresed, and probed with a JAK3 
cDNA. Expression of G3PDH demonstrated  the relative amounts of RNA loaded in each lane. 
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cytes were stimulated for 18 h with nothing (lane 1), 1,000 U/ml ID2, 
500 U/ml IFN-% 100 U/ml IL-4, 100 ng/ml Ib7, or 100 ng/ml LPS (hnes 
2-6, respectively).  Total  RNA was extracted  and analyzed  for  JAK3 mRNA. 
RNA loading was quantitated using expression  of G3PDH. 
able only after prolonged exposure of the immunoblots. 
JAK3 Phosphorylation in Response to IL-2,  IL-4, and IL-7 
in Activated Monocytes.  Having established that monocytes 
express  high levels of JAK3 after stimulation with  IFN-3  ~ 
and LPS, we asked whether JAK3 might be involved in the 
cytokine signal transduction pathways of human monocytes. 
Cells were preactivated then stimulated with various cytokines, 
and tyrosine phosphorylation of JAK3 was assessed.  Fig.  5 
shows that high levels of tyrosine phosphorylation of  JAK3 
were observed in response to IL-2,  IL-4, or IL-7, but not 
GM-CSF or IFN-% Stripping of this blot followed by direct 
immunoblotting of  JAK3 (Fig. 5, bottom) demonstrated that 
the cytokine treatments did not affect the quantity of  JAK3 
immunoprecipitated. In addition, as suggested by our previous 
findings in T cells (8, 11), preliminary data indicate that IL-4 
Figure 5.  Tyrosine  phosphorylation  of  JAK3 in response to ID2, Ib4, 
and Ib7. Primed monocytes  were either unstimulated (lane 1) or treated 
with 1,000 U/m1 ID2 (lane 2), 100 U/ml ID4 (lane 3), 100 ng/ml Ib7 
(lane 4), 500 U/ml IFN-v (lane 5), or 100 ng/ml GM-CSF (lane 6) for 
10 rain, then lysed; immunoprecipitated  JAK3 was immunoblotted  with 
monoclonal  antiphosphotyrosine  antibody  (top), then polyclonal  anti-JAK3 
(bottom). 
stimulation of monocytes results in the tyrosine phosphory- 
lation of  JAK1 as well as JAK3 (data not shown). These data 
suggested that, in monocytes, JAK3 is coupled to three dis- 
tinct cytokine receptors that use the %  chain. 
Discussion 
We have recently reported that  the newest Janus kinase, 
JAK3, is coupled to the receptors for IL-2 and IL-4 in T and 
NK ceils (7, 8,  11). We reported that JAK3 was not detect- 
able in resting human monocytes, but others described con- 
stitutive JAK3 expression in a murine myeloid cell line (11, 
20).  Here we  resolve this  discrepancy by confirming our 
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Figure  4.  Expression  of  JAK3 pro- 
tein after stimulation with  Yc cyto- 
kines. (A) Cells were stimulated as in 
Fig. 3, lanes 1-6, or with both 100 
ng/ml LPS and 500 U/ml IFN-~/(lane 
7). Postnuclear  lysates were immuno- 
blotted with JAK3 antiserum. (B) Ly- 
sates from  control  (lane  I) or LPS-stim- 
ulated cells  (lane  2) were  immunoblotted 
with JAK3 in the presence  of cognate 
JAK3 peptide. previous findings and expanding them to demonstrate that 
JAK3 expression is highly regulated in monocytes. Whereas 
resting monocytes express very low levels of  JAK3, we show 
that potent monocyte activators  such as IL-2,  IFN-% and 
LPS  all  induce JAK3  expression,  and  that  some human 
factor-dependent myeloid cell lines  constitutively express 
JAK3. In addition, we demonstrate that JAK3 in monocytes 
is tyrosine phosphorylated in response to IL-2, IL-4, or IL-7 
treatment. 
The Janus family is now known to be involved in the signal 
transduction pathways of several cytokines that use receptors 
of the hematopoietin family (3, 4). Currently, the family con- 
sists of four proteins JAK1, JAK2, and Tyk2, all ubiquitously 
expressed, and the most recently described member, JAK3, 
a kinase predominantly expressed in NK and activated T cells 
(8, 7, 11, 20, 26). The induction of JAK3 in monocytes by 
IFN-~/and LPS that we report here is not surprising given 
the potent effects these agents have on monocyte function. 
However, the induction of JAK3 by IL-2 becomes the first 
demonstration of  JAK3 protein regulation by a cytokine that 
signals via this kinase. These data suggest that IL-2 can in- 
duce JAK3 even in resting monocytes in which JAK3 ex- 
pression is minimal. Whereas at present we can only specu- 
late as to how signaling occurs under this circumstance, a 
possible explanation for this apparent paradox is that the re- 
sponses of a population of resting monocytes to IL-2 or IL-4 
represents an autocrine response begun by a subset of preac- 
tivated monocytes expressing higher levels of JAK3. Alter- 
natively, these data could indicate the participation of kinases 
other than JAK3 in the cytokine response of resting mono- 
cytes. Both of these possibilities are currently under investi- 
gation. Regardless, a model requiring stimulation of mono- 
cytes to achieve full IL-2 responsiveness is supported by the 
fact that relatively high amounts of IL-2 are needed to stimulate 
resting monocytes as compared to preactivated cells (27). 
Moreover, preactivation of monocytes with IL-2, IFN-% or 
LPS induces bothJAK3 and IL-2Rot chains (28, 29) resulting 
in higher levels of high affinity IL-2 receptor,  more JAK3 
for signal transduction, and as a result, an increase in the 
sensitivity of monocytes to stimulation with low doses of IL-2. 
In addition to activated lymphoid cells, high JAK3 expres- 
sion has been reported in the murine myeloid cell line 32D 
(11). When these cells are transfected with the IL-2 receptor, 
JAK3 is tyrosine phosphorylated in response to IL-2 (11). 
Here we have demonstrated that the M07e cell line, derived 
from a patient with megakaryobhstic leukemia (30), expresses 
JAK3 constitutively. Moreover, our data show that these cells 
use JAK3 in the signal transduction pathways  of their en- 
dogenous IL-2 and IL-4 receptors but not those for GM-CSF 
or IFN-3'. Taken together, these data suggest an important 
role for JAK3  in  the cytokine responses  of this myeloid 
leukemia cell line. It should be noted, however, that a screen 
of 40 primary marrow aspirates from patients with acute my- 
eloid leukemia detected only four that expressed significant 
levels of  JAK3 protein (data not shown). The overall impor- 
tance of JAK3 in myeloid leukemia is under further investi- 
gation. 
Our current findings that, in addition to IL-2 and IL-4, 
JAK3 is tyrosine phosphorylated in response to IL-7, dem- 
onstrate that JAR3 may be a critical signal transduction mol- 
ecule in the pathway of all of the cytokine receptors currently 
known to use the % chain. The established  associations of 
JAK3 with IL-2,  IL-4,  and IL-7 signaling dictate that fur- 
ther elucidation of the specific roles of JAR3 in monocyte 
cytokine responses, such as the identification of specific sub- 
strates and intracellular interactions, should lead to a better 
understanding of the overall regulation of monocyte func- 
tion during an immune response. 
The cytokines IL-2, IL-4, and 11,-7 play important but diver- 
gent roles in monocyte development and maturation, making 
it important to explore the differences among the signaling 
pathways  elicited by each of these factors.  Clearly,  the use 
of JAK3 by all known % receptors suggests that, at the level 
of JAK kinases, the signal transduction pathways for these 
cytokines are similar.  However,  cytokine-induced tyrosine 
phosphorylation ofJAK kinases is followed by tyrosine phos- 
phorylation of latent SH2, SH3 domain containing transcrip- 
tion factors known as signal transducers and activators of tran- 
scription, or STAT proteins (31, 32). Therefore, the tyrosine 
phosphorylated STAT or STAT-like proteins that result from 
the binding of various % receptors may, in part, determine 
signal specificity. Consistent with this hypothesis, apparently 
distinct tyrosine phosphorylated DNA binding proteins now 
are known to be associated with both IL-2 and IL-4 stimula- 
tion (33-35). Thus, whereas JAK3 and % represent similar 
mechanisms by which IL-2, IL-4, and IL-7 signal, the points 
at which these pathways diverge towards their cytokine-specific 
effects will require further investigation. 
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